Saturday, 4 September 2010
|
||||
| Boston | Delft | Tokyo | ||
Pyxis Discovery provides chemistry-based lead discovery services to companies that are active in small molecule drug discovery.
Our Smart Approach for designing and selecting screening compound libraries, which is based on the principles of leadlikeness, facilitates a rapid and efficient lead discovery process, yielding lead compounds with excellent pharmacological profiles.
Pyxis Discovery also hosts Chemonaut, a compound sourcing platform which enables you to search an online database with the compound offerings of more than 50 vendors.
A unique feature of the Chemonaut database is that the screening compound structures are filtered for leadlikeness. More than 70 structural filters are used, ensuring that now everybody can have access to a huge high quality database and compound collection, consisting of almost 5 million unique screening compounds and 900,000 unique building blocks.
Visit www.chemonaut.com to explore this service of Pyxis Discovery.
In the October 2006 issue of Molecular Diversity, one of the leading cheminformatics publications in drug discovery, an analysis performed by Pyxis Discovery can be found.
The full reference of the paper is: Verheij, H.J., Molecular Diversity 10 (2006), 3, 377-388. The online publication can be obtained by clicking here.
Click here for an overview of the upcoming events that Pyxis Discovery will attend.
Target Immobilized NMR Screening (TINS) is one of the latest developments in fragment based screening. Just like any other of these techniques, it requires a well-tuned library of fragments in order to obtain a diverse set of screening hits.
For one of the drug discovery projects in which Pyxis Discovery is involved, we have selected a set of 2,000 fragments, based on 4 different design approaches. The structures have been filtered for undesired functionalities, using an in-house designed set of structural filters that encodes for leadlikeness. A small set of preferred functional groups (polar or hydrophobic) was also filtered for, in order to both enhance binding properties and follow-up synthetic possibilities of the fragments.
This set of compounds was finally selected for maximum scaffold diversity using Xu's 'Scaffold-based Classification Approach', a method that clusters compounds based on the complexity of their scaffold.
The fragments are available for screening at ZoBio (Leiden, The Netherlands), using their TINS platform.
